Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Sage Therapeutics, Inc. (SAGE)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 58,290,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 3,000 25,500
Total Buy Value $0 $0 $87,779 $839,364
Total People Bought 0 0 1 3
Total Buy Transactions 0 0 2 4
Total Shares Sold 0 0 0 11,643
Total Sell Value $0 $0 $0 $519,413
Total People Sold 0 0 0 1
Total Sell Transactions 0 0 0 1
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 261
  Page 7 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Paul Steven M   –       •      –    2017-01-31 4 A $3.15 $6,848 D/D 2,174 690,851     -
   Starr Kevin P Director   –       •      –    2017-01-23 4 D $0.00 $0 I/I (1,000,000) 1,892,916     -
   Iguchi Kimi CFO, Secretary and Treasurer   •       –      –    2017-01-13 4 AS $53.92 $539,200 D/D (10,000) 66,498     -
   Anderson Thomas See Remarks   •       –      –    2016-12-15 4 D $48.99 $16,951 D/D (346) 1,554     -
   Anderson Thomas See Remarks   •       –      –    2016-12-15 4 OE $8.92 $16,948 D/D 1,900 1,900     -
   Robichaud Albert Chief Scientific Officer   •       –      –    2016-12-13 4 GD $0.00 $0 D/D 500 154,259     -
   Robichaud Albert Chief Scientific Officer   •       –      –    2016-12-09 4 GD $0.00 $0 D/D 500 154,759     -
   Robichaud Albert Chief Scientific Officer   •       –      –    2016-12-08 4 GD $0.00 $0 D/D 250 155,259     -
   Iguchi Kimi CFO, Secretary and Treasurer   •       –      –    2016-11-17 4 AS $51.77 $207,080 D/D (4,000) 75,739     -
   Anderson Thomas See Remarks   •       –      –    2016-11-15 4 AS $55.00 $550,000 D/D (10,000) 0     -
   Anderson Thomas See Remarks   •       –      –    2016-11-15 4 OE $8.92 $89,200 D/D 10,000 10,000     -
   Iguchi Kimi CFO, Secretary and Treasurer   •       –      –    2016-11-11 4 AS $50.59 $75,885 D/D (1,500) 79,739     -
   Robichaud Albert Chief Scientific Officer   •       –      –    2016-10-28 4 OE $1.36 $20,790 D/D 15,287 155,509     -
   Iguchi Kimi CFO, Secretary and Treasurer   •       –      –    2016-09-07 4 AS $40.93 $102,325 D/D (2,500) 81,239     -
   Tepper Robert I 10% Owner   –       –       •   2016-08-19 4 D $0.00 $0 D/D (1,000,000) 2,892,916     -
   Starr Kevin P Director   –       •       •   2016-08-19 4 D $0.00 $0 I/I (1,000,000) 2,892,916     -
   Robichaud Albert Chief Scientific Officer   •       –      –    2016-07-12 4 AS $40.00 $880,000 D/D (22,000) 140,222     -
   Iguchi Kimi CFO, Secretary and Treasurer   •       –      –    2016-07-12 4 AS $49.55 $247,750 D/D (5,000) 83,739     -
   Tepper Robert I 10% Owner   –       –       •   2016-05-16 4 S $31.25 $26,562,500 D/D (850,000) 3,892,916     -
   Starr Kevin P Director   –       •       •   2016-05-16 4 S $31.25 $26,562,500 I/I (850,000) 3,892,916     -
   Kanes Stephen Chief Medical Officer   •       –      –    2016-04-20 4 OE $0.45 $9,450 D/D 21,000 46,948     -
   Kanes Stephen Chief Medical Officer   •       –      –    2016-04-19 4 AS $38.00 $798,000 D/D (21,000) 25,948     -
   Paul Steven M   –       •      –    2016-02-23 4 GD $0.00 $0 I/I 5,081 678,569     -
   Robichaud Albert Chief Scientific Officer   •       –      –    2016-01-25 4 AS $40.02 $800,400 D/D (20,000) 162,222     -
   Jonas Jeffrey M See Remarks   •       •      –    2016-01-07 4 OE $0.45 $9,000 D/D 20,000 101,226     -
  261 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us